Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
991 DKK | +1.15% |
|
+0.71% | +41.96% |
06-14 | Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy | RE |
06-14 | Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B | |
-3.71% | 116B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies